A two-year follow-up of neonates with presumed sepsis treated with recombinant human granulocyte colony-stimulating factor during the first week of life

Rosenthal, Joseph; Healey, Timothy; Ellis, Robin; Gillan, Eileen; Cairo, Mitchell S.

doi:10.1016/s0022-3476(96)70443-2

Cited by 62 publications

(27 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients affected by other types of neutropenia such as cyclic or idiopathic neutropenia are not at an increased risk of MDS and leukemia when treated over long periods of time with G-CSF according to the Severe Chronic Neutropenia International Registry [8]. Additionally, no progression to MDS and leukemia was described in a 2-year follow-up of neonates treated for sepsis with G-CSF [9]. Our study compared global gene expression in peripheral blood mononuclear cells of healthy donors in intervals ranging from 62 to 314 days after G-CSF administration to gene expression before therapy.…”

Section: Discussionmentioning

confidence: 99%

Changes in Gene Expression Pattern following Granulocyte Colony-Stimulating Factor Administration to Normal Stem Cell Sibling Donors

Amariglio¹,

Jacob‐Hirsch²,

Shimoni³

et al. 2006

Acta Haematol

View full text Add to dashboard Cite

Granulocyte colony-stimulating factor (G-CSF) is widely used for the mobilization of hematopoietic stem cells from normal donors. The mechanism of induced mobilization has recently been elucidated. Treatment with G-CSF is considered safe; however, long-term effects are largely unknown. The aim of this study was, therefore, to determine whether it leads to significant changes in gene expression modifications. Affymetrix Gene Chip array technology was used. Samples were collected before and at various time points (up to 9 months) after mobilization. The expression levels of 122 genes were transiently modified before and after mobilization (p < 0.05). Fifty-three genes belonging to cell growth, proliferation and communication gene ontology categories were upregulated, while 69 genes were downregulated. Conclusion: The administration of G-CSF is associated with transient DNA and gene expression modifications in the lymphocytes of normal mobilized donors. A long-term follow-up of stem cell donors is recommended.

show abstract

Section: Discussionmentioning

confidence: 99%

Changes in Gene Expression Pattern following Granulocyte Colony-Stimulating Factor Administration to Normal Stem Cell Sibling Donors

Amariglio¹,

Jacob‐Hirsch²,

Shimoni³

et al. 2006

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…A similar lack of evidence of long-term adverse hematologic effects has been noted in a 2-year follow-up of neonates treated with G-CSF for sepsis. 23 Studies in normal adult PBSC donors have shown no late effects associated with short-term G-CSF therapy with 3-6 years of follow-up. 24,25 Other studies in normal donors showed no lingering DNA instability 2-4 weeks after cytokine use and normal T, B, and NK cell counts a year after donation.…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: The Pediatric Blood and Marrow Transplant Consortium Experience (PBMTC) 1996–2003

Pulsipher

Levine

Hayashi

et al. 2004

Bone Marrow Transplant

101

View full text Add to dashboard Cite

Summary:The use of peripheral blood stem cells (PBSC) for allogeneic transplants in adults has greatly increased. This trend is reflected in pediatrics, where healthy children increasingly are donating PBSC or donor lymphocyte infusion (DLI) via apheresis for use by ill siblings. There is a potential concern that the risks of PBSC collection may differ for pediatric donors. However, no large studies have assessed safety issues in this population. To address this need, we reviewed 218 (213 PBSC, five DLI) collections in 201 normal pediatric donors (8 months to 17 years, median 11.8 years) at 22 institutions in the Pediatric Blood and Marrow Transplant Consortium. Donors received a median of 4 days of growth factor, and mean collection yield was 9.1 Â 10 6 CD34 þ cells/kg recipient weight. Younger age, days of apheresis, and male gender predicted increased yield of CD34 þ cells/kg donor weight. Growth factor-induced pain was mild and reported in less than 15% of patients. Most donors o20 kg (23/25, 92%) required PRBC priming of the apheresis machine. This experience with over 200 collections demonstrates that PBSC collection is safe in normal pediatric donors and desired CD34 cell yields are easily achieved. Younger children utilize more medical resources and children o20 kg usually require a single blood product exposure.

show abstract

“…Although high levels of G-CSF in newborns have been described, the incidence and severity of bacterial infections is increased because of quantitative and qualitative deficiencies of granulopoiesis and neutrophil functions [3][4][5]. Therapy with rhG-CSF in human neonates with presumed sepsis resulted in sustained neutrophilia and improvement of neutrophil functions [33][34][35][36][37]. Since G-CSF exerts its biologic activities through binding to its specific receptor, high levels of G-CSF may be necessary to compensate low expression of G-CSF receptor of neutrophils from newborns in order to improve impaired neutrophil functions.…”

Section: Discussionmentioning

confidence: 99%

Decreased mRNA Expression of G-CSF Receptor in Cord Blood Neutrophils of Term Newborns

Gessler¹,

Neu²,

Brockmann³

et al. 2000

Neonatology

View full text Add to dashboard Cite

Granulocyte colony-stimulating factor (G-CSF) promotes neutrophil production and enhances neutrophil function. The effects of G-CSF are mediated by binding to its receptor. Since neutrophils are an essential part of the neonatal host defense system, we studied G-CSF receptor expression in neonatal neutrophils. We determined protein and mRNA expression of G-CSF receptor in freshly isolated neutrophils from cord blood of healthy term newborns (n = 16) and of adults (n = 6) as well as the in vitro effect of supplemented recombinant human G-CSF (rhG-CSF) and tumor necrosis factor-α (TNF-α) on G-CSF receptor expression of neutrophils. Expression of G-CSF receptor on the surface of neutrophils of cord blood was significantly lower compared to adults (61 ± 6 vs. 89 ± 2%). G-CSF receptor mRNA transcripts of neutrophils from newborns compared to adults was lower, too (77 ± 14 vs. 152 ± 33%). Neutrophils isolated from cord blood showed a decrease of G-CSF receptor expression within 24 h of culture. Moreover, we were able to show that supplemented rhG-CSF is necessary for maintenance of G-CSF receptor expression. TNF-α, however, down-regulated G-CSF receptor expression. We conclude that low protein and mRNA expression of G-CSF receptor in neutrophils of neonates compared to adults may adversely affect granulopoiesis and neutrophil functions by decreased responsiveness to G-CSF. Furthermore, G-CSF receptor expression on neutrophils was modified not only by G-CSF itself, but also by TNF-α.

show abstract

A two-year follow-up of neonates with presumed sepsis treated with recombinant human granulocyte colony-stimulating factor during the first week of life

Cited by 62 publications

References 4 publications

Changes in Gene Expression Pattern following Granulocyte Colony-Stimulating Factor Administration to Normal Stem Cell Sibling Donors

Changes in Gene Expression Pattern following Granulocyte Colony-Stimulating Factor Administration to Normal Stem Cell Sibling Donors

Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: The Pediatric Blood and Marrow Transplant Consortium Experience (PBMTC) 1996–2003

Decreased mRNA Expression of G-CSF Receptor in Cord Blood Neutrophils of Term Newborns

Contact Info

Product

Resources

About